Skip to main content

The Molecular Pathology of Precursor Lesions of Pancreatic Cancer

  • Living reference work entry
  • First Online:
Pancreatic Cancer
  • 138 Accesses

Abstract

It has become evident over the past decade that pancreatic ductal adenocarcinoma (PDAC) does not originate de novo, but rather, through a multistep progression that involves histologically defined precursor lesions. Three major subtypes of precursor lesions of PDAC have been identified to date, including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN). PanINs constitute by far the most common precursor lesion, and are, by definition, microscopic in nature, while IPMNs and MCNs occur less frequently and are macroscopic (e.g., radiographically detectable) precursor lesions. In addition to the development of consensus histopathological criteria for the identification and classification of PDAC precursors, there has also been considerable progress made in characterizing the genetic alterations underlying these lesions. Elucidating the molecular pathology of precursor lesions has enabled a better understanding of the pathogenesis of early pancreatic neoplasia, and provided a seedbed for developing tools for early detection and chemoprevention of PDAC. The histopathology, molecular genetics as well as clinical implications and possible directions for future research of PanINs, IPMNs, and MCNs will be discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Similar content being viewed by others

References

  1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.

    Article  CAS  PubMed  Google Scholar 

  2. Hulst SLP. Zur Kenntnis der Genese des Adenokarzinoms und Karzinoms des Pankreas. Virchows Archiv. 1905;180:288–316.

    Article  Google Scholar 

  3. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–87.

    Article  PubMed  Google Scholar 

  4. Hruban RH, Maitra A, Kern SE, et al. Precursors to pancreatic cancer. Gastroenterol Clin North Am. 2007;36:831–49.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690–8.

    CAS  PubMed  Google Scholar 

  6. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003;16:996–1006.

    Article  PubMed  Google Scholar 

  7. Agoff SN, Crispin DA, Bronner MP, et al. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol. 2001;14:139–46.

    Article  CAS  PubMed  Google Scholar 

  8. Stelow EB, Adams RB, Moskaluk CA. The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am J Surg Pathol. 2006;30:36–41.

    Article  PubMed  Google Scholar 

  9. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902–12.

    Article  PubMed  Google Scholar 

  10. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54.

    Article  CAS  PubMed  Google Scholar 

  11. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730–733.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–50.

    Article  CAS  PubMed  Google Scholar 

  14. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17:3112–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev. 2003;13:6–13.

    Article  CAS  PubMed  Google Scholar 

  16. Baines AT, Lim KH, Shields JM, et al. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol. 2006;407:556–74.

    Article  CAS  PubMed  Google Scholar 

  17. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243–7.

    Article  CAS  PubMed  Google Scholar 

  18. Laghi L, Orbetegli O, Bianchi P, et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene. 2002;21:4301–6.

    Article  CAS  PubMed  Google Scholar 

  19. Sherr CJ. Cell cycle control and cancer. Harvey Lect. 2000;96:73–92.

    PubMed  Google Scholar 

  20. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27–32.

    Article  CAS  PubMed  Google Scholar 

  21. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126–30.

    CAS  PubMed  Google Scholar 

  22. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998;58:4740–4.

    CAS  PubMed  Google Scholar 

  23. Rosty C, Geradts J, Sato N, et al. p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol. 2003;27:1495–501.

    Article  PubMed  Google Scholar 

  24. Hustinx SR, Hruban RH, Leoni LM, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther. 2005;4:83–6.

    CAS  PubMed  Google Scholar 

  25. Hustinx SR, Leoni LM, Yeo CJ, et al. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol. 2005;18:959–63.

    Article  CAS  PubMed  Google Scholar 

  26. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.

    Article  CAS  PubMed  Google Scholar 

  27. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025–33.

    CAS  PubMed  Google Scholar 

  28. Hahn SA, Hoque AT, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56:490–4.

    CAS  PubMed  Google Scholar 

  29. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782:197–228.

    Article  CAS  PubMed  Google Scholar 

  30. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.

    Article  CAS  PubMed  Google Scholar 

  31. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature. 2006;441:1015–9.

    Article  CAS  PubMed  Google Scholar 

  32. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002–6.

    CAS  PubMed  Google Scholar 

  34. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.

    Article  CAS  PubMed  Google Scholar 

  35. van der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003;63:2585–8.

    PubMed  Google Scholar 

  36. van der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651–7.

    Article  PubMed  PubMed Central  Google Scholar 

  37. D’Andrea AD, Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer. 2003;3:23–34.

    Article  PubMed  CAS  Google Scholar 

  38. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:342–6.

    Article  CAS  PubMed  Google Scholar 

  39. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J. 2001;7:266–73.

    CAS  PubMed  Google Scholar 

  40. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000;156:1767–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol. 2002;161:1541–7.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Yamano M, Fujii H, Takagaki T, et al. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol. 2000;156:2123–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.

    Article  CAS  PubMed  Google Scholar 

  44. Sato N, Fukushima N, Hruban RH, et al. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol. 2008;21:238–44.

    Article  CAS  PubMed  Google Scholar 

  45. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006;27:1160–8.

    Article  CAS  PubMed  Google Scholar 

  46. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol. 2007;34:303–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614–22.

    CAS  PubMed  Google Scholar 

  48. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002;62:2890–6.

    CAS  PubMed  Google Scholar 

  49. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649–57.

    CAS  PubMed  Google Scholar 

  50. Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene. 2005;24:6626–36.

    Article  CAS  PubMed  Google Scholar 

  51. Nakamura T, Furukawa Y, Nakagawa H, et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004;23:2385–400.

    Article  CAS  PubMed  Google Scholar 

  52. Tanaka M, Komatsu N, Terakawa N, et al. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 2007;18:161–6.

    CAS  PubMed  Google Scholar 

  53. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–8.

    CAS  PubMed  Google Scholar 

  54. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008;7:286–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Segara D, Biankin AV, Kench JG, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res. 2005;11:3587–96.

    Article  CAS  PubMed  Google Scholar 

  56. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009;8:2013–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009;33:698–709.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18:981–92.

    Article  PubMed  Google Scholar 

  60. Klein WM, Hruban RH, Klein-Szanto AJ, et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol. 2002;15:441–7.

    Article  PubMed  Google Scholar 

  61. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res. 2001;61:8830–7.

    CAS  PubMed  Google Scholar 

  62. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–90.

    CAS  PubMed  Google Scholar 

  63. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194–201.

    Article  CAS  PubMed  Google Scholar 

  64. Sclabas GM, Uwagawa T, Schmidt C, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005;103:2485–90.

    Article  CAS  PubMed  Google Scholar 

  65. Bloomston M, Zervos EE, Rosemurgy AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002;9:668–74.

    Article  PubMed  Google Scholar 

  66. Crawford HC, Scoggins CR, Washington MK, et al. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002;109:1437–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. O’Mahony CA, Seidel A, Albo D, et al. Angiostatin generation by human pancreatic cancer. J Surg Res. 1998;77:55–8.

    Article  PubMed  Google Scholar 

  68. Ribatti D, Leali D, Vacca A, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci. 1999;112(Pt 23):4213–21.

    CAS  PubMed  Google Scholar 

  69. Harvey SR, Hurd TC, Markus G, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res. 2003;9:4935–43.

    CAS  PubMed  Google Scholar 

  70. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846–51.

    Article  CAS  PubMed  Google Scholar 

  71. Doucas H, Garcea G, Neal CP, et al. Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer. 2005;41:365–79.

    Article  CAS  PubMed  Google Scholar 

  72. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3:565–76.

    Article  CAS  PubMed  Google Scholar 

  73. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.

    Article  CAS  PubMed  Google Scholar 

  74. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Prasad NB, Biankin AV, Fukushima N, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005;65:1619–26.

    Article  CAS  PubMed  Google Scholar 

  77. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349–54.

    Article  CAS  PubMed  Google Scholar 

  78. Pasca di Magliano M, Biankin AV, Heiser PW, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One. 2007;2:e1155.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Al-Aynati MM, Radulovich N, Riddell RH, et al. Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res. 2004;10:1235–40.

    Article  CAS  PubMed  Google Scholar 

  80. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006;66:95–106.

    Article  CAS  PubMed  Google Scholar 

  81. Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut. 2008;57:1420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008;5:e123.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Funahashi H, Satake M, Dawson D, et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007;67:7068–71.

    Article  CAS  PubMed  Google Scholar 

  84. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81; quiz 665.

    Google Scholar 

  85. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–76.

    PubMed  PubMed Central  Google Scholar 

  86. Terhune PG, Phifer DM, Tosteson TD, et al. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev. 1998;7:515–21.

    CAS  PubMed  Google Scholar 

  87. Yu J, Sadakari Y, Shindo K, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66:1677–87.

    Google Scholar 

  88. Reid-Lombardo KM, St Sauver J, Li Z, et al. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984–2005: a population study. Pancreas. 2008;37:139–44.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–97.

    Article  PubMed  Google Scholar 

  90. Scheiman JM, Hwang JH, Moayyedi P. American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:824–48.e22.

    Article  PubMed  Google Scholar 

  91. Adsay V, Mino-Kenudson M, Furukawa T, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of Verona Consensus Meeting. Ann Surg. 2016;263:162–77.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8:213–9.

    Article  PubMed  Google Scholar 

  93. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–85; discussion 685–7.

    Google Scholar 

  94. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12:81–91.

    Article  PubMed  Google Scholar 

  95. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol. 2000;24:1372–7.

    Article  CAS  PubMed  Google Scholar 

  96. Seki M, Yanagisawa A, Ohta H, et al. Surgical treatment of intraductal papillary-mucinous tumor (IPMT) of the pancreas: operative indications based on surgico-pathologic study focusing on invasive carcinoma derived from IPMT. J Hepatobiliary Pancreat Surg. 2003;10:147–55.

    Article  PubMed  Google Scholar 

  97. Tanaka M. Intraductal papillary mucinous neoplasm of the pancreas: diagnosis and treatment. Pancreas. 2004;28:282–8.

    Article  PubMed  Google Scholar 

  98. Seidel G, Zahurak M, Iacobuzio-Donahue C, et al. Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol. 2002;26:56–63.

    Article  PubMed  Google Scholar 

  99. Adsay NV, Pierson C, Sarkar F, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001;25:26–42.

    Article  CAS  PubMed  Google Scholar 

  100. Kamisawa T, Tu Y, Egawa N, et al. Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol. 2005;11:5688–90.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Nikiforova MN, Khalid A, Fasanella KE, et al. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol. 2013;26:1478–87.

    Article  CAS  PubMed  Google Scholar 

  102. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Singhi AD, Nikiforova MN, Fasanella KE, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20:4381–9.

    Article  CAS  PubMed  Google Scholar 

  104. Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011;108:21188–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Amato E, Molin MD, Mafficini A, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233:217–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Kanda M, Sadakari Y, Borges M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013;11:719–30.e5.

    Article  CAS  PubMed  Google Scholar 

  108. Garcia-Carracedo D, Chen ZM, Qiu W, et al. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas. 2014;43:245–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Garcia-Carracedo D, Turk AT, Fine SA, et al. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2013;19:6830–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Sasaki S, Yamamoto H, Kaneto H, et al. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep. 2003;10:21–5.

    CAS  PubMed  Google Scholar 

  111. Biankin AV, Biankin SA, Kench JG, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50:861–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Hata T, Dal Molin M, Suenaga M, et al. Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas. Clin Cancer Res. 2016;22:5141–51.

    Article  CAS  PubMed  Google Scholar 

  113. House MG, Guo M, Iacobuzio-Donahue C, et al. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 2003;24:193–8.

    Article  CAS  PubMed  Google Scholar 

  114. Sato N, Ueki T, Fukushima N, et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2002;123:365–72.

    Article  CAS  PubMed  Google Scholar 

  115. Sato N, Fukushima N, Maitra A, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol. 2004;164:903–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Ohuchida K, Mizumoto K, Fujita H, et al. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice. J Pathol. 2006;210:42–8.

    Article  CAS  PubMed  Google Scholar 

  117. Nishikawa N, Kimura Y, Okita K, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features. J Hepatobiliary Pancreat Surg. 2006;13:327–35.

    Article  PubMed  Google Scholar 

  118. Cheung W, Darfler MM, Alvarez H, et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology. 2008;8:608.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Siveke JT, Einwachter H, Sipos B, et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell. 2007;12:266–79.

    Article  CAS  PubMed  Google Scholar 

  120. Taki K, Ohmuraya M, Tanji E, et al. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Oncogene. 2016;35:2407–12.

    Article  CAS  PubMed  Google Scholar 

  121. Dal Molin M, Hong SM, Hebbar S, et al. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol. 2012;43:585–91.

    Article  CAS  PubMed  Google Scholar 

  122. von Figura G, Fukuda A, Roy N, et al. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol. 2014;16:255–67.

    Article  CAS  Google Scholar 

  123. Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22; quize12–3.

    Google Scholar 

  124. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.

    Article  PubMed  Google Scholar 

  125. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol. 2005;3:967–73.

    Article  CAS  PubMed  Google Scholar 

  126. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009;69:1095–102.

    Article  PubMed  Google Scholar 

  127. Shen J, Brugge WR, Dimaio CJ, et al. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer. 2009;117:217–27.

    PubMed  Google Scholar 

  128. Panarelli NC, Sela R, Schreiner AM, et al. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions. Am J Surg Pathol. 2012;36:1434–43.

    Article  PubMed  Google Scholar 

  129. Toll AD, Kowalski T, Loren D, et al. The added value of molecular testing in small pancreatic cysts. JOP. 2010;11:582–6.

    PubMed  Google Scholar 

  130. Singhi AD, Zeh HJ, Brand RE, et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc. 2016;83:1107–1117.e2.

    Article  PubMed  Google Scholar 

  131. Jones M, Zheng Z, Wang J, et al. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc. 2016;83:140–8.

    Article  PubMed  Google Scholar 

  132. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas, Atlas of tumor pathology. Fourth series, Fascicle 6th edition. Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007.

    Google Scholar 

  133. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999;23:410–22.

    Article  CAS  PubMed  Google Scholar 

  134. Bassi C, Salvia R, Gumbs AA, et al. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3. Langenbecks Arch Surg. 2002;387:281–5.

    Article  PubMed  Google Scholar 

  135. Zamboni G, Kloppel G, Hruban R, et al. Mucinous cystic neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 234–6.

    Google Scholar 

  136. Jimenez RE, Warshaw AL, Z’Graggen K, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501–9; discussion 509–11.

    Google Scholar 

  137. Fukushima N, Sato N, Prasad N, et al. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene. 2004;23:9042–51.

    Article  CAS  PubMed  Google Scholar 

  138. Lam MM, Swanson PE, Upton MP, et al. Ovarian-type stroma in hepatobiliary cystadenomas and pancreatic mucinous cystic neoplasms: an immunohistochemical study. Am J Clin Pathol. 2008;129:211–8.

    Article  PubMed  Google Scholar 

  139. Mao J, Ligon KL, Rakhlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 2006;66:10171–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11:229–43.

    Article  CAS  PubMed  Google Scholar 

  141. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008;247:571–9.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Lewis GH, Wang H, Bellizzi AM, et al. Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2013;37:601–5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anirban Maitra .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this entry

Cite this entry

Singhi, A.D., Maitra, A. (2017). The Molecular Pathology of Precursor Lesions of Pancreatic Cancer. In: Neoptolemos, J., Urrutia, R., Abbruzzese, J., Büchler, M. (eds) Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6631-8_5-2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6631-8_5-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-6631-8

  • Online ISBN: 978-1-4939-6631-8

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics